GenFleet Therapeutics (Shanghai) Inc. (Stock Code: 02595), a joint-stock company incorporated in the PRC, has announced that its board of directors will convene on Tuesday, 24 March 2026. The meeting’s primary agenda includes:
• Approval and publication of the consolidated annual results for the financial year ended 31 December 2025. • Consideration of a recommendation regarding the payment of a final dividend, if any.
The announcement was released in Hong Kong on 12 March 2026.
Board composition at the date of the notice is as follows: Executive Directors – Dr. Qiang Lu (Chairman), Dr. Jiong Lan, and Ms. Zhang Wei; Non-Executive Directors – Mr. Zhu Jingyang and Ms. Tao Sha; Independent Non-Executive Directors – Ms. Christine Shaohua Lu-Wong, Dr. Zhou Demin, and Mr. Li Bo.